GlassScriptPhysician profile
Nathan Charapata
NPI 1578982864
$719.99
in general payments reported to CMS, 2019-2025
15 companies · $32.64 in 2025
The $32.64 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $203 · 2021: $89.36 · 2023: $19.71 · 2025: $32.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $52.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $52.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $239.88 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $123.93 | 2019-2020 | |
| Abbvie INC. | $52.35 | 2023-2025 | Avycaz |
| Novo Nordisk INC | $47.35 | 2019-2020 | |
| Mylan Specialty L.P. | $44.72 | 2019-2020 | |
| Pfizer INC. | $40.36 | 2019 | |
| Merck Sharp & Dohme LLC | $30.64 | 2019-2021 | |
| Merz North America, INC. | $27.56 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.48 | 2019 | |
| Biodelivery Sciences International, INC. | $17.57 | 2020 | |
| Ge Healthcare | $16.79 | 2019 | |
| Lilly USA, LLC | $16.26 | 2021 | |
| Eisai INC. | $16.17 | 2020 | |
| Amgen INC. | $15.53 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $12.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Charapata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.